Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Trial Profile

A Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Retinal oedema
  • Focus Adverse reactions; Proof of concept
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 17 Jan 2019 According to an Aerie Pharmaceuticals media release, the US FDA has accepted the IND application for AR-1105. The company plans to initiate this study in the first quater of 2019.
    • 20 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top